Trending...
- The One Experience™, Inc. Announces Presenting Sponsors and Partners for Flagship Event
- Discover the Culinary Heart of Le Marche: A 5-Night Food & Wine Tour + Farm to Table Cooking Classes in Italy's Hidden Gem
- Introducing HOME-OMETRY, the Social Media Network for Real Estate
CCHR says the conflicted alliance of the psychiatric-pharmaceutical industry is rife in psychiatry's diagnostic manual, as confirmed in a new study that found $14.2 million in payouts to contributors
LOS ANGELES - ncarol.com -- A recent British Medical Journal study has revealed that more than half of the doctors who contributed to the latest edition of the American Psychiatric Association's (APA) Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) had conflicts of interest with the pharmaceutical-health industry, collectively receiving $14.2 million. The DSM, often referred to as psychiatry's "billing bible," not only serves as a tool for obtaining reimbursement in mental health treatment but also plays a central role in approving new psychiatric drugs and is used for clinical drug trials.[1] The Citizens Commission on Human Rights International, a watchdog in the mental health industry, has been campaigning for over two decades to advocate for the public disclosure of financial ties between pharmaceutical companies and mental health care practitioners. The group emphasizes that conflicts of interest have the potential to influence clinical results with bias.
The researchers in the study include Lisa Cosgrove, a professor from the University of Massachusetts-Boston, Department of Counseling and School Psychology, who has conducted previous studies exposing conflicts of interest for DSM-IV and DSM-5. The current study addresses the latest revision, DSM-5-TR, published in 2022. The percentage of panel members with industry support was similar between DSM-5-TR and DSM-5.
The study identifies 168 individuals who served as either panel or task force members of the DSM-5-TR, of which 92 were based in the U.S. and subject to disclosure of their interests in the Open Payments Program. Of these 92, 55 (60%) received payments from industry.
Open Payments is a Centers for Medicare & Medicaid Services publicly accessible database that identifies monies given by pharmaceutical and device companies to individual physicians and institutions. Since 2013, under the Physician Payments Sunshine Act, all drug and device manufacturers are required to disclose these payments.
Such transparency is not available or easily accessible in other countries. Therefore, as the researchers point out, the study only used information provided by Open Payments, which does not include payments to physicians based outside the U.S. That's a substantial number of experts unaccounted for. According to the APA, approximately 21% of the participants in DSM-5-TR were international experts.[2]
More on ncarol.com
Congruent with previous studies, "panel members of the DSM who received the most remuneration from drug companies were those working in diagnostic areas where drug interventions are often the standard treatment…."
The top 5 DSM disorders for financial disclosures determined from Open Payments, are:
Neuroleptic malignant syndrome was listed as a mental disorder in DSM-IV. Patients can exhibit NMS symptoms within 2 weeks and nearly all within 30 days of taking an antipsychotic.[4]
Neuroleptics cause involuntary movement of the lips, tongue, jaw, fingers, toes and other body parts, known as Tardive Dyskinesia (TD). CCHR says it's a "revolving door" effect: antipsychotics are prescribed, cause a disfiguring condition, which is, in turn, diagnosed as another mental disorder, for which a second or third drug is prescribed—with more side effects.[5]
Common adverse effects of one approved TD-treatment drug include: trouble with balance, coordination or walking, drooling, irregular heartbeat, and restlessness, inability to sit still, need to keep moving, and trembling and shaking of the fingers or hands—similar symptoms to the antipsychotics themselves.[6]
There are 12 psychiatrists listed as members of the DSM-5-TR medication-induced movement disorders Work Party, headed by a former APA president. That psychiatrist came under federal Senate investigation in 2008 because of his undisclosed conflicts of interest with the pharmaceutical industry, when he had 15 links to drug companies, including stock ownership.[7] Between 2019 and 2022, Open Payments reported he received nearly $104,000 in industry payments.[8] A 2022 disclosure lists his financial ties to two pharmaceutical companies that manufacture antipsychotics that can cause medication-induced movement disorders.[9]
More on ncarol.com
In 2020, IQVia's Total Patient Tracker shows more than 11.1 million were taking antipsychotics. That equates to potentially 2.23 and 5.57 million Americans being permanently damaged from drug-induced movement disorders such as TD.[10]
Add to this the psychiatrist's financial association with the company COMPASS, which conducts psilocybin (magic mushrooms) psychedelic drug research.[11] Psychedelics can cause another DSM disorder: Hallucinogen-persisting Perception Disorder.[12]
The DSM is controversial because task force members vote to include a mental disorder in the manual. The disorders are not discovered in the way medical illnesses are. There are no physical tests or blood work to confirm a DSM disorder. After being voted into existence, a psychiatric drug can be prescribed for it.
Carl Elliott, a bioethicist at the University of Minnesota says: "The way to sell drugs is to sell psychiatric illness."[13]
Nearly 77 million Americans now take psychiatric drugs.[14]
CCHR recommends people read Mental Disorders: The Facts Behind The Marketing Campaign on its website and access its psychiatric drugs side effects database to become further educated on the issue.
About CCHR: CCHR was founded in 1969 by the Church of Scientology and the late Dr. Thomas Szasz, Professor of Psychiatry, and prolific author of books on psychiatry. It has helped achieve over 190 laws enacted that protect rights within the mental health system and bring to account violations of rights.
[1] www.bmj.com/content/384/bmj-2023-076902
[2] www.psychiatry.org/getmedia/5635958b-ee71-4352-b02a-fb24ecab86c6/APA-DSM5TR-ThePeopleBehindDSM.pdf
[3] www.cchrint.org/2017/02/27/experts-expose-troubling-facts-about-the-psycho-pharma-industry/; dsm.psychiatryonline.org/doi/10.1176/appi.books.9780890425787.Medication_Induced_Movement_Disorders
[4] www.ncbi.nlm.nih.gov/pmc/articles/PMC3726098/; www.ncbi.nlm.nih.gov/pmc/articles/PMC6478951/
[5] www.cchrint.org/2021/10/11/consumers-beware-of-antipsychotics-long-term-debilitating-effects/
[6] www.cchrint.org/2021/10/11/consumers-beware-of-antipsychotics-long-term-debilitating-effects/
[7] www.cchrint.org/2010/12/31/american-psychiatric-associations-interests-in-conflict/
[8] openpaymentsdata.cms.gov/physician/340355
[9] clinicaloptions.com/CE-CME/slideset:-potential-drugs-of-abuse-as-antidepressants/100008767
[10] www.cchrint.org/2021/10/11/consumers-beware-of-antipsychotics-long-term-debilitating-effects/
[11] compasspathways.com/
[12] www.ncbi.nlm.nih.gov/pmc/articles/PMC5870365/
[13] www.cchrint.org/issues/dsm-billing-bible/; www.washingtonpost.com/archive/politics/2001/07/16/drug-ads-hyping-anxiety-make-some-uneasy/8fe2eea2-b780-48cd-9872-1d3802e83147/
[14] www.cchrint.org/psychiatric-drugs/people-taking-psychiatric-drugs/
The researchers in the study include Lisa Cosgrove, a professor from the University of Massachusetts-Boston, Department of Counseling and School Psychology, who has conducted previous studies exposing conflicts of interest for DSM-IV and DSM-5. The current study addresses the latest revision, DSM-5-TR, published in 2022. The percentage of panel members with industry support was similar between DSM-5-TR and DSM-5.
The study identifies 168 individuals who served as either panel or task force members of the DSM-5-TR, of which 92 were based in the U.S. and subject to disclosure of their interests in the Open Payments Program. Of these 92, 55 (60%) received payments from industry.
Open Payments is a Centers for Medicare & Medicaid Services publicly accessible database that identifies monies given by pharmaceutical and device companies to individual physicians and institutions. Since 2013, under the Physician Payments Sunshine Act, all drug and device manufacturers are required to disclose these payments.
Such transparency is not available or easily accessible in other countries. Therefore, as the researchers point out, the study only used information provided by Open Payments, which does not include payments to physicians based outside the U.S. That's a substantial number of experts unaccounted for. According to the APA, approximately 21% of the participants in DSM-5-TR were international experts.[2]
More on ncarol.com
- Malcolm-Jamal Warner Returns to Columbia for an Unforgettable Evening of Poetry & Music
- Slightly Stoopid, Damian & Stephen Marley to headline Everwild Music Festival in 2025
- Parkbench13 Media Group Inc. Seeks Artists for Sync Licensing Opportunities
- The Elevated Table Project Revolutionizes Cannabis-Infused Cooking & Cocktails
- Kuester Management Group Provides Expert Guidance for Ethical and Effective HOA Leadership
Congruent with previous studies, "panel members of the DSM who received the most remuneration from drug companies were those working in diagnostic areas where drug interventions are often the standard treatment…."
The top 5 DSM disorders for financial disclosures determined from Open Payments, are:
- Medication-induced movement disorders: $8,443,468
- Sleep-wake disorders: $1,892,430
- Disruptive, impulse, and conduct disorders: $1,059,910
- Obsessive Compulsive Disorder: $973,851
- Depressive disorders: $875,373
Neuroleptic malignant syndrome was listed as a mental disorder in DSM-IV. Patients can exhibit NMS symptoms within 2 weeks and nearly all within 30 days of taking an antipsychotic.[4]
Neuroleptics cause involuntary movement of the lips, tongue, jaw, fingers, toes and other body parts, known as Tardive Dyskinesia (TD). CCHR says it's a "revolving door" effect: antipsychotics are prescribed, cause a disfiguring condition, which is, in turn, diagnosed as another mental disorder, for which a second or third drug is prescribed—with more side effects.[5]
Common adverse effects of one approved TD-treatment drug include: trouble with balance, coordination or walking, drooling, irregular heartbeat, and restlessness, inability to sit still, need to keep moving, and trembling and shaking of the fingers or hands—similar symptoms to the antipsychotics themselves.[6]
There are 12 psychiatrists listed as members of the DSM-5-TR medication-induced movement disorders Work Party, headed by a former APA president. That psychiatrist came under federal Senate investigation in 2008 because of his undisclosed conflicts of interest with the pharmaceutical industry, when he had 15 links to drug companies, including stock ownership.[7] Between 2019 and 2022, Open Payments reported he received nearly $104,000 in industry payments.[8] A 2022 disclosure lists his financial ties to two pharmaceutical companies that manufacture antipsychotics that can cause medication-induced movement disorders.[9]
More on ncarol.com
- THSYU Opens New Doors for Accredited Investors, Bridging the Gap Between Traditional Finance and the Digital Asset Frontier
- Gold Coast Health Plan Among State's Top Performers for Outstanding Health Care Quality
- NC Health Official Urges Ban on Wilderness Therapy Camps Following Child's Death
- Breaking Barriers & Elevating Voices: The Top 50 Over 50 Podcast Awards Set to Make History!
- The Power Of Online Reviews & Why They Matter
In 2020, IQVia's Total Patient Tracker shows more than 11.1 million were taking antipsychotics. That equates to potentially 2.23 and 5.57 million Americans being permanently damaged from drug-induced movement disorders such as TD.[10]
Add to this the psychiatrist's financial association with the company COMPASS, which conducts psilocybin (magic mushrooms) psychedelic drug research.[11] Psychedelics can cause another DSM disorder: Hallucinogen-persisting Perception Disorder.[12]
The DSM is controversial because task force members vote to include a mental disorder in the manual. The disorders are not discovered in the way medical illnesses are. There are no physical tests or blood work to confirm a DSM disorder. After being voted into existence, a psychiatric drug can be prescribed for it.
Carl Elliott, a bioethicist at the University of Minnesota says: "The way to sell drugs is to sell psychiatric illness."[13]
Nearly 77 million Americans now take psychiatric drugs.[14]
CCHR recommends people read Mental Disorders: The Facts Behind The Marketing Campaign on its website and access its psychiatric drugs side effects database to become further educated on the issue.
About CCHR: CCHR was founded in 1969 by the Church of Scientology and the late Dr. Thomas Szasz, Professor of Psychiatry, and prolific author of books on psychiatry. It has helped achieve over 190 laws enacted that protect rights within the mental health system and bring to account violations of rights.
[1] www.bmj.com/content/384/bmj-2023-076902
[2] www.psychiatry.org/getmedia/5635958b-ee71-4352-b02a-fb24ecab86c6/APA-DSM5TR-ThePeopleBehindDSM.pdf
[3] www.cchrint.org/2017/02/27/experts-expose-troubling-facts-about-the-psycho-pharma-industry/; dsm.psychiatryonline.org/doi/10.1176/appi.books.9780890425787.Medication_Induced_Movement_Disorders
[4] www.ncbi.nlm.nih.gov/pmc/articles/PMC3726098/; www.ncbi.nlm.nih.gov/pmc/articles/PMC6478951/
[5] www.cchrint.org/2021/10/11/consumers-beware-of-antipsychotics-long-term-debilitating-effects/
[6] www.cchrint.org/2021/10/11/consumers-beware-of-antipsychotics-long-term-debilitating-effects/
[7] www.cchrint.org/2010/12/31/american-psychiatric-associations-interests-in-conflict/
[8] openpaymentsdata.cms.gov/physician/340355
[9] clinicaloptions.com/CE-CME/slideset:-potential-drugs-of-abuse-as-antidepressants/100008767
[10] www.cchrint.org/2021/10/11/consumers-beware-of-antipsychotics-long-term-debilitating-effects/
[11] compasspathways.com/
[12] www.ncbi.nlm.nih.gov/pmc/articles/PMC5870365/
[13] www.cchrint.org/issues/dsm-billing-bible/; www.washingtonpost.com/archive/politics/2001/07/16/drug-ads-hyping-anxiety-make-some-uneasy/8fe2eea2-b780-48cd-9872-1d3802e83147/
[14] www.cchrint.org/psychiatric-drugs/people-taking-psychiatric-drugs/
Source: Citizens Commission on Human Rights International
0 Comments
Latest on ncarol.com
- Turbocharge Small- and Medium-Size Business Financing with Faster Funding's Innovative Business Credit Building and Financing Suite
- Inframark's Oklahoma City Team Wins OWEA Awards, Exemplary Employer Accolade
- Vintage Jewelry Company - We Buy Gold Opens in Fayetteville, NC
- Hitachi Construction Machinery estabelece sede regional na América Latina no Chile
- Hitachi Construction Machinery establece su sede regional para América Latina en Chile
- Hitachi Construction Machinery Establishing Latin American Regional Headquarters in Chile
- APV Delivers High-Intensity Performance with Capella Heat Exchanger Plates
- New Book Further Unravels the Myth of a "Chemical Imbalance" Causing Depression
- Master P Launches Fishbone Express: A New Seafood Sensation
- FBI Agents in Operation Bullpen Allegedly Used Patriot Act to Spy on Fraud Suspects, Including Stan Fitzgerald -VFAF
- MEDIA ADVISORY: Leaders Across Georgia Gather in Atlanta for Georgia Municipal Association's Cities United Summit
- Enter the Dragon - PermianMuseum.com adds a Winged Dragon Fossil
- The Lightwell House: Kata Walters Brings Global Inspiration to Chapel Hill
- Unity Locale - West Dallas by CivilizedX: A Celebration of Culture, Creativity, and Community
- Save 15 Percent with KeysCaribbean's Last-Minute Booking or 90-Day Advance Purchase Discounts
- AirBox is First to Market with High-Volume Air Purification for IAQP Commercial Application
- Kaplan Morrell Attorney Ronda Cordova Recognized in The Best Lawyers in America® for Workers' Compensation Law – Claimants
- BEPeterson awarded Air Flask order from the Navel Supply Systems Command (NAVSUP)
- RE1 Advisor Introduces RE1 Disaster Recovery
- Amid Controversy with The Weeknd/Playboi Carti and Buzz Surrounding His Upcoming Project, Darrin Jones Drops Soulful New Single "Under Control"